# Phase I of XKH002 Injection in Patients

> **NCT06196762** · PHASE1 · UNKNOWN · sponsor: **Zhejiang Kanova Biopharmaceutical Co., LTD** · enrollment: 110 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** XKH002 Injection

## Key facts

- **NCT ID:** NCT06196762
- **Lead sponsor:** Zhejiang Kanova Biopharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-27
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196762, "Phase I of XKH002 Injection in Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06196762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*